70 related articles for article (PubMed ID: 17980767)
1. RAD inhibition of sarcoma growth: implications for laryngeal transplantation.
Knott PD; Tamai H; Strome M; Van Lente F; Shu S
Am J Otolaryngol; 2007; 28(6):375-8. PubMed ID: 17980767
[TBL] [Abstract][Full Text] [Related]
2. Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII).
Khariwala SS; Kjaergaard J; Lorenz R; Van Lente F; Shu S; Strome M
Laryngoscope; 2006 May; 116(5):814-20. PubMed ID: 16652094
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses.
Majewski M; Korecka M; Joergensen J; Fields L; Kossev P; Schuler W; Shaw L; Wasik MA
Transplantation; 2003 May; 75(10):1710-7. PubMed ID: 12777861
[TBL] [Abstract][Full Text] [Related]
4. Differential effect of cyclosporine A and SDZ RAD on neointima formation of carotid allografts in apolipoprotein E-deficient mice.
Matsumoto Y; Hof A; Baumlin Y; Hof RP
Transplantation; 2003 Oct; 76(8):1166-70. PubMed ID: 14578747
[TBL] [Abstract][Full Text] [Related]
5. Laryngeal transplantation in the setting of cancer: a rat model.
Shipchandler TZ; Lorenz RR; Lee WT; Teker AM; Dan O; Strome M
Laryngoscope; 2008 Dec; 118(12):2166-71. PubMed ID: 18948827
[TBL] [Abstract][Full Text] [Related]
6. The tumor suppressive reagent taurolidine inhibits growth of malignant melanoma--a mouse model.
Braumann C; Jacobi CA; Rogalla S; Menenakos C; Fuehrer K; Trefzer U; Hofmann M
J Surg Res; 2007 Dec; 143(2):372-8. PubMed ID: 17612567
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects on pulmonary metastases of low-dose consecutive administration of cisplatin on sarcoma-bearing mice.
Takeda A; Tsuchiya H; Tajino T; Sato K; Kikuchi S
Anticancer Res; 2003; 23(1A):309-13. PubMed ID: 12680229
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
Ross H; Pflugfelder P; Haddad H; Cantarovich M; White M; Ignaszewski A; Howlett J; Vaillancourt M; Dorent R; Burton JR;
J Heart Lung Transplant; 2008 Feb; 27(2):197-202. PubMed ID: 18267227
[TBL] [Abstract][Full Text] [Related]
9. [Rhodiola sachalinensis suppresses T241 fibrosarcoma tumor cells proliferation in vitro and growth in vivo].
Zhao X; Zuo L; Zhong ZQ
Zhong Yao Cai; 2008 Sep; 31(9):1377-80. PubMed ID: 19180963
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
Mita MM; Mita AC; Chu QS; Rowinsky EK; Fetterly GJ; Goldston M; Patnaik A; Mathews L; Ricart AD; Mays T; Knowles H; Rivera VM; Kreisberg J; Bedrosian CL; Tolcher AW
J Clin Oncol; 2008 Jan; 26(3):361-7. PubMed ID: 18202410
[TBL] [Abstract][Full Text] [Related]
11. Treatment of murine tumors using dual-frequency ultrasound in an experimental in vivo model.
Barati AH; Mokhtari-Dizaji M; Mozdarani H; Bathaie SZ; Hassan ZM
Ultrasound Med Biol; 2009 May; 35(5):756-63. PubMed ID: 19195770
[TBL] [Abstract][Full Text] [Related]
12. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model.
Mach CM; Mathew L; Mosley SA; Kurzrock R; Smith JA
Anticancer Res; 2009 Jun; 29(6):1895-9. PubMed ID: 19528445
[TBL] [Abstract][Full Text] [Related]
13. A combination of donor specific transfusion and rapamycin prolongs cardiac allograft survival in mice.
Wu K; Xiang F; Yuan J; Zeng Z; Zhou H; Chang S; Chen ZK
Transplant Proc; 2008 Dec; 40(10):3699-701. PubMed ID: 19100468
[TBL] [Abstract][Full Text] [Related]
14. Prolongation of corneal allograft survival by topical application of everolimus in experimental keratoplasty.
Li XQ; Buch G; Otasevic L; Schlickeiser S; Bertelmann E; Pleyer U
Ophthalmic Res; 2008 Oct; 40(6):309-14. PubMed ID: 18688173
[TBL] [Abstract][Full Text] [Related]
15. Long-term limb allograft survival using a short course of anti-CD45RB monoclonal antibody, LF 15-0195, and rapamycin in a mouse model.
Zhong T; Liu Y; Jiang J; Wang H; Temple CL; Sun H; Garcia B; Zhong R; Ross DC
Transplantation; 2007 Dec; 84(12):1636-43. PubMed ID: 18165776
[TBL] [Abstract][Full Text] [Related]
16. [Rapamycin combined with donor bone marrow-derived immature dendritic cells induces mouse skin allograft tolerance].
Yu S; He X; Hu A; Fu BM; Ma Y
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Mar; 28(3):399-402. PubMed ID: 18359700
[TBL] [Abstract][Full Text] [Related]
17. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
Albano L; Berthoux F; Moal MC; Rostaing L; Legendre C; Genin R; Toupance O; Moulin B; Merville P; Rerolle JP; Bayle F; Westeel PF; Glotz D; Kossari N; Lefrançois N; Charpentier B; Blanc AS; Di Giambattista F; Dantal J;
Transplantation; 2009 Jul; 88(1):69-76. PubMed ID: 19584683
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature.
Murphy JD; Spalding AC; Somnay YR; Markwart S; Ray ME; Hamstra DA
Clin Cancer Res; 2009 Jan; 15(2):589-96. PubMed ID: 19147764
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients.
Böhler T; Waiser J; Lichter S; Schumann B; Neumayer HH; Kamar N; Budde K
Cytokine; 2008 Jun; 42(3):306-11. PubMed ID: 18440821
[TBL] [Abstract][Full Text] [Related]
20. Effect of a metalloporphyrin antioxidant (MnTE-2-PyP) on the response of a mouse prostate cancer model to radiation.
Makinde AY; Luo-Owen X; Rizvi A; Crapo JD; Pearlstein RD; Slater JM; Gridley DS
Anticancer Res; 2009 Jan; 29(1):107-18. PubMed ID: 19331139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
